logo

RKDA

Arcadia Biosciences·NASDAQ
--
--(--)
--
--(--)
9.78 / 10
Outperform

RKDA's fundamental assessment is excellent at 9.8/10, driven by a 66.27% YoY profit growth and a favorable PB-ROE score. However, cash-flow metrics are negative, with Net cash flow / Revenue at -98% and Net cash flow / Total liabilities at -1.23, signaling liquidity strain that could offset otherwise solid earnings. The stock ranks in the top quartile for several key ratios, but cash-flow weakness prevents a perfect score.

Fundamental(9.78)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.10
Score1/3
Weight-5.49%
1M Return-0.38%
Annualized return on equity (%)
Value-22.93
Score3/3
Weight35.54%
1M Return1.98%
Net cash flow from operating activities / Operating revenue (%)
Value-98.00
Score0/3
Weight-75.39%
1M Return-5.66%
Profit-MV
Value0.46
Score3/3
Weight77.62%
1M Return4.32%
Net income-Revenue
Value0.89
Score1/3
Weight8.73%
1M Return0.49%
PB-ROE
Value-0.50
Score3/3
Weight90.28%
1M Return4.62%
Net cash flow from operating activities / Total liabilities (%)
Value-1.23
Score0/3
Weight-73.78%
1M Return-5.17%
ROE (%)
Value-17.20
Score3/3
Weight35.54%
1M Return1.98%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value66.27
Score3/3
Weight41.68%
1M Return2.28%
Cash-MV
Value-0.07
Score1/3
Weight-34.73%
1M Return-2.56%
Is RKDA undervalued or overvalued?
  • RKDA scores 9.78/10 on fundamentals and holds a Discounted valuation at present. Backed by its -17.20% ROE, -97.95% net margin, -0.41 P/E ratio, 0.57 P/B ratio, and 10.58% earnings growth, these metrics solidify its Outperform investment rating.